Compass Therapeutics reports FY2023 net loss of $42.5M; CTX-009 data expected by end 2024

Compass Therapeutics, Inc.

Net loss $42.5M ($0.33/share) vs $39.2M loss in 2022; R&D expenses rose 27% to $38.1M.
Cash and marketable securities $152.5M at Dec 31, 2023; runway into mid-2026.
CTX-009 Phase 2/3 BTC study (COMPANION-002) enrollment ongoing; top-line data expected year-end 2024.
CTX-009 Phase 2 CRC study (COMPANION-003) Stage 1 enrollment complete; top-line data mid-2024.
CTX-471 Phase 2 monotherapy planning underway for melanoma with novel biomarker; combination arm with KEYTRUDA enrolling.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Compass Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was $42.5 million or $0.33 per common share, EPS $0.33 per common share.

Period: the year ended December 31, 2023
Net income: Net loss for the year ended December 31, 2023, was $42.5 million or $0.33 per common share
EPS: $0.33 per common share
Result: reported results

Exact text from the filing

On March 21, 2024, Compass Therapeutics, Inc. issued a press release announcing financial results for the year ended December 31, 2023.

View on SEC.gov

1049 earnings releases filed in the last 30 days. Browse all earnings releases →

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-001515

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.